What is the Madrey score cut off for initiating prednisone (corticosteroid) therapy in patients with alcoholic hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maddrey Score Cut-off for Prednisone in Alcoholic Hepatitis

The Maddrey Discriminant Function (mDF) score cut-off for initiating prednisone therapy in alcoholic hepatitis is ≥32, which defines severe alcoholic hepatitis requiring corticosteroid treatment. 1, 2

Assessment of Disease Severity

  • Severe alcoholic hepatitis is defined by a Maddrey Discriminant Function (mDF) score ≥32, MELD score >20-21, Glasgow Alcoholic Hepatitis Score (GAHS) ≥9, or presence of hepatic encephalopathy 1, 2
  • Patients with mDF <32 were previously considered to have "non-severe" alcoholic hepatitis, but this terminology is now discouraged as these patients still have approximately 20% 1-year mortality 1
  • Current terminology recommends using "symptomatic alcoholic hepatitis with moderate severity" for patients with mDF <32 and "symptomatic alcoholic hepatitis with severe severity" for those with mDF ≥32 1

Treatment Recommendations Based on Maddrey Score

  • Patients with mDF <32 (moderate alcoholic hepatitis) should be monitored closely but typically do not require nor benefit from specific medical interventions beyond nutritional support and alcohol abstinence 1, 2
  • Patients with mDF ≥32 (severe alcoholic hepatitis) and lacking contraindications to steroid use should receive prednisolone 40 mg/day for 28 days, typically followed by discontinuation or a 2-week taper 1, 2
  • The therapeutic window for maximum benefit from corticosteroids is in patients with MELD scores between 25 and 39, with a 21-30% survival benefit 3

Monitoring Response to Treatment

  • Response to corticosteroid therapy should be assessed at day 7 using the Lille model 1, 2
  • A Lille score <0.45 indicates good response (responders) with 70-85% 6-month survival 1, 2
  • A Lille score ≥0.45 indicates poor response (non-responders) with 20-30% 6-month survival 1
  • For patients with Lille score ≥0.56 (null responders), corticosteroid therapy should be discontinued as it provides no benefit over placebo 1
  • Early Change in Bilirubin Level (ECBL) at day 7 is another marker of response - patients with confirmed ECBL have 82% 6-month survival versus only 23% in those without ECBL 1, 4

Contraindications to Corticosteroid Therapy

  • Corticosteroids are contraindicated in patients with 2:
    • Active infection or sepsis
    • Gastrointestinal bleeding
    • Acute renal failure
    • Acute pancreatitis

Alternative Therapies

  • Pentoxifylline (400 mg orally three times daily for 4 weeks) can be considered for patients with severe alcoholic hepatitis (mDF >32) who have contraindications to steroid therapy 1, 2
  • However, pentoxifylline is less effective than prednisolone for improving survival but may reduce the risk of hepatorenal syndrome 1, 5

Common Pitfalls and Caveats

  • Infection screening should be performed in all patients with alcoholic hepatitis before initiating corticosteroid therapy, as infection is a contraindication 1, 6
  • Long-term outcomes depend primarily on achieving alcohol abstinence, which should be strongly recommended to all patients 2, 6
  • Nutritional support is crucial in alcoholic hepatitis management, with recommendation for high-calorie (30-40 kcal/kg/day) and high-protein (1.2-1.5 g/kg/day) diet 6
  • Corticosteroid benefit is lost in patients with extremely severe disease (MELD >51), highlighting the importance of timely intervention 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Steroid Treatment for Severe Alcoholic Hepatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Bilirubin response to corticosteroids in severe alcoholic hepatitis.

European journal of gastroenterology & hepatology, 2005

Guideline

Initial Treatment for Alcoholic Hepatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.